103 results
Page 2 of 6
8-K
EX-99.1
kuqjz6 9zarjr
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
9h1ujuyw gs
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
t9jez36flq6 kg4
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
qyt1 07wcny
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
2g0h36
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
u6h0dcl9sv7f3 zp
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRE 14A
zw0p3sz
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-99.1
9ts8q1 ndofr
3 Apr 23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:17pm
8-K
EX-99.1
z82rpj3
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
zu9h8ihxdoq8f6l2g2xw
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
f5ocqd ben88
29 Mar 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
1esmrj p5aujq8vieoo9
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
ufzd96tt8al f2j
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm